Stock ARVN ARVINAS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Arvinas, Inc.

Equities

ARVN

US04335A1051

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
31.44 USD -1.60% Intraday chart for Arvinas, Inc. -4.20% -23.62%
05-08 Oppenheimer Adjusts Arvinas Price Target to $70 From $80, Maintains Outperform Rating MT
05-07 Arvinas Shares Up After Q1 Net Loss Narrows MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arvinas Shares Up After Q1 Net Loss Narrows
MT
Earnings Flash (ARVN) ARVINAS Reports Q1 Revenue $25.3M
MT
Arvinas, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug
MT
Novartis: licensing agreement in prostate cancer
CF
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis
MT
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact
DJ
Novartis licenses Arvinas' cancer drug for up to $1 billion
RE
Arvinas, Inc Enters into an Exclusive Strategic License Agreement with Novartis AG for the Development and Commercialization of Protac Androgen Receptor Protein Degrader Arv-766 for the Treatment of Prostate Cancer
CI
Arvinas' Q4 Net Loss Widens as Company Reports No Revenue
MT
Arvinas, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Arvinas, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
North American Morning Briefing : S&P 500 Seen -2-
DJ
Arvinas, Inc. and Pfizer Inc. Announces That the U.S. Food and Drug Administration Has Granted Fast Track Designation for the Investigation of Vepdegestrant (Arv-471) for Monotherapy
CI
Arvinas, Inc. and Pfizer Inc. Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®?) and Plans to Expand Vepdegestrant Development Program
CI
Earnings Flash (ARVN) ARVINAS Posts Q3 Revenue $34.6M
MT
Arvinas, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Arvinas, Inc. Announces the Presentation of Interim Data from the its Phase 1/2 Clinical Trial for Bavdegalutamide
CI
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023
CI
Earnings Flash (ARVN) ARVINAS Posts Q2 Revenue $54.5M
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARVN Stock
  4. News Arvinas, Inc.
  5. Highlights